Monoketocholate can decrease transcellular permeation of methotrexate across Caco-2 cell monolayers and reduce its intestinal absorption in rat

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 7, 2009, Pages 953-959

  Chen, Gong ^a   Fawcett, J Paul ^a   Mikov, Momir ^a   Tucker, Ian G ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

12 monoketocholate; Caco 2 cell permeation; Methotrexate; Pharmacokinetics; Rat

Indexed keywords

BILE SALT; CARBON 14; CHOLIC ACID; MANNITOL; METHOTREXATE; MONOKETOCHOLATE; SODIUM 12 MONOKETOCHOLATE; SODIUM DERIVATIVE; UNCLASSIFIED DRUG; 3,7 DIHYDROXY 12 OXOCHOLANOIC ACID; 3,7-DIHYDROXY-12-OXOCHOLANOIC ACID; CHENODEOXYCHOLIC ACID; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; PHARMACEUTICAL VEHICLES AND ADDITIVES;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL PERMEABILIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ABSORPTION; DRUG HALF LIFE; ELECTRIC RESISTANCE; EXPERIMENTAL STUDY; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; MALE; MONOLAYER CULTURE; NONHUMAN; RAT; ANIMAL; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; DOSE RESPONSE; DRUG EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ORAL DRUG ADMINISTRATION; TRANSPORT AT THE CELLULAR LEVEL; WISTAR RAT;

ADJUVANTS, PHARMACEUTIC; ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; CHENODEOXYCHOLIC ACID; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL ABSORPTION; MALE; METHOTREXATE; RATS; RATS, WISTAR; SODIUM CHOLATE;

EID: 85047682917     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.61.07.0016     Document Type: Article

References (41)

1. Vlahcevic ZR et al. Regulation of bile acid biosynthesis. Gastroenterol Clin North Am 1999; 28(1): 1-25, v.
2. Alrefai WA, Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res 2007; 24(10): 1803-1823.
3. Mithani SD et al. Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharm Res 1996; 13(1): 163-167.
4. Vyvoda OS et al. Effects of different bile salts upon the composition and morphology of a liver plasma membrane preparation. Deoxycholate is more membrane damaging than cholate and its conjugates. Biochim Biophys Acta 1977; 465(1): 68-76.
5. Hajjar JJ et al. Effect of bile salts on amino acid transport by rabbit intestine. Am J Physiol 1975; 229(2): 518-523.
6. Said HM, Hollander D. Inhibitory effect of bile salts on the enterohepatic circulation of methotrexate in the unanesthetized rat: inhibition of methotrexate intestinal absorption. Cancer Chemother Pharmacol 1986; 16(2): 121-124.
7. Assaraf YG. Molecular basis of antifolate resistance. Cancer Metastasis Rev 2007; 26(1): 153-181.
8. Honscha W, Petzinger E. Characterization of the bile acid sensitive methotrexate carrier of rat liver cells. Naunyn Schmiedebergs Arch Pharmacol 1999; 359(5): 411-419.
9. Nakai Y et al. Functional characterization of human proton-coupled folate transporter/heme carrier protein 1 heterologously expressed in mammalian cells as a folate transporter. J Pharmacol Exp Ther 2007; 322(2): 469-476.
10. Tanaka Y et al. Tissue distribution and hormonal regulation of the breast cancer resistance protein (Bcrp/Abcg2) in rats and mice. Biochem Biophys Res Commun 2005; 326(1): 181-187.
11. Mottino AD et al. Expression and localization of multidrug resistant protein mrp2 in rat small intestine. J Pharmacol Exp Ther 2000; 293(3): 717-723.
12. Rost D et al. Expression and localization of the multidrug resistance-associated protein 3 in rat small and large intestine. Am J Physiol Gastrointest Liver Physiol 2002; 282(4): G720-G726.
13. Yokooji T et al. Role of intestinal efflux transporters in the intestinal absorption of methotrexate in rats. J Pharm Pharmacol 2007; 59(9): 1263-1270.
14. Lo YL, Huang JD. Effects of sodium deoxycholate and sodium caprate on the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. Biochem Pharmacol 2000; 59(6): 665-672.
15. Ingels F et al. Effect of simulated intestinal fluid on drug permeability estimation across Caco-2 monolayers. Int J Pharm 2004; 274(1-2): 221-232.
16. Mazzoni A, Trave F. Cytoplasmic membrane cholesterol and doxorubicin cytotoxicity in drug-sensitive and multidrug-resistant human ovarian cancer cells. Oncol Res 1993; 5(2): 75-82.
17. Storch CH et al. Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro. J Pharmacol Exp Ther 2007; 323(1): 257-264.
18. Posa M et al. Determination of critical micellar concentrations of cholic acid and its keto derivatives. Colloids Surf B Biointerfaces 2007; 59(2): 179-183.
19. Yang L et al. Physicochemical and biological characterization of monoketocholic acid, a novel permeability enhancer. Mol Pharm 2009; 6(2): 448-456.
20. Xia CQ et al. Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells. Drug Metab Dispos 2005; 33(5): 637-643.
21. Prime-Chapman HM et al. Differential multidrug resistance-associated protein 1 through 6 isoform expression and function in human intestinal epithelial Caco-2 cells. J Pharmacol Exp Ther 2004; 311(2): 476-484.
22. Subramanian VS et al. Differentiation-dependent regulation of the intestinal folate uptake process: studies with Caco-2 cells and native mouse intestine. Am J Physiol Cell Physiol 2008; 295(3): C828-C835.
23. Li Y et al. Transport and metabolism of MitoQ10, a mitochondria-targeted antioxidant, in Caco-2 cell monolayers. J Pharm Pharmacol 2007; 59(4): 503-511.
24. Yu H et al. Evidence for diminished functional expression of intestinal transporters in Caco-2 cell monolayers at high passages. Pharm Res 1997; 14(6): 757-762.
25. Beck O et al. Trace analysis of methotrexate and 7-hydroxymethotrexate in human plasma and urine by a novel high-performance liquid chromatographic method. Ther Drug Monit 1991; 13(6): 528-532.
26. Cociglio M et al. Determination of methotrexate and 7-hydroxymethotrexate by liquid chromatography for routine monitoring of plasma levels. J Chromatogr B Biomed Appl 1995; 674(1): 101-110.
27. Bolton S. Pharmaceutical Statistics: Practical and Clinical Applications, 3rd edn. New York: Marcel Dekker, 1997.
28. Aungst BJ. Intestinal permeation enhancers. J Pharm Sci 2000; 89(4): 429-442.
29. Sakai M et al. Simultaneous use of sodium deoxycholate and dipotassium glycyrrhizinate enhances the cellular transport of poorly absorbed compounds across Caco-2 cell monolayers. J Pharm Pharmacol 1999; 51(1): 27-33.
30. Balakrishnan A, Polli JE. Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target. Mol Pharm 2006; 3(3): 223-230.
31. Haimeur A et al. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 2004; 5(1): 21-53.
32. Said HM et al. Inhibitory effect of unconjugated bile acids on the enterohepatic circulation of methotrexate. J Pharmacol Exp Ther 1984; 231(3): 660-664.
33. Hayashi M, Tomita M. Mechanistic analysis for drug permeation through intestinal membrane. Drug Metab Pharmacokinet 2007; 22(2): 67-77.
34. Lazorova L et al. Quantification and imaging of mannitol transport through Caco-2 cell monolayers using a positronemitting tracer. Pharm Res 1998; 15(7): 1141-1144.
35. Kruh GD et al. Physiological and pharmacological functions of Mrp2, Mrp3 and Mrp4 as determined from recent studies on gene-disrupted mice. Cancer Metastasis Rev 2007; 26(1): 5-14.
36. Seelig A, Gerebtzoff G. Enhancement of drug absorption by noncharged detergents through membrane and P-glycoprotein binding. Expert Opin Drug Metab Toxicol 2006; 2(5): 733-752.
37. Zeng H et al. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res 2001; 61(19): 7225-7232.
38. Lowes S, Simmons NL. Human intestinal cell monolayers are preferentially sensitive to disruption of barrier function from basolateral exposure to cholic acid: correlation with membrane transport and transepithelial secretion. Pflugers Arch 2001; 443(2): 265-273.
39. Kuroda T et al. Species differences in oral bioavailability of methotrexate between rats and monkeys. Biol Pharm Bull 2000; 23(3): 334-338.
40. Said S et al. Methotrexate. Clin Dermatol 1997; 15(5): 781-797.
41. Dupuis LL et al. Influence of food on the bioavailability of oral methotrexate in children. J Rheumatol 1995; 22(8): 1570-1573.